Under the Paperwork Reduction Act of 1995, no persons are required to

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

	Application Number		11616659		
Filing Date			2003-07-09		
	First Named Inventor	MARA	ANAS, Costas D.	_	
	Art Unit		1631	_	
	Examiner Name	SKOV	WRONEK, Karlheinz R.	_	
	Attorney Docket Number		P06367US03	_	

					U.S.I	PATENTS			Remove		
Examiner Initial*	xaminer Cite Patent Number Kind Issue Date Name of Patentee or Applicant Ri		Releva	Pages,Columns,Lines where Relevant Passages or Releva Figures Appear							
	1										
If you wisl	h to a	ı dd additional U.S. Pate	nt citatio	n inform	ation pl	lease click the	Add button.		Add		
			U.S.P	ATENT	APPLIC	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	of cited Decument		Releva		Lines where ges or Relev	
	1										
If you wish	h to a	dd additional U.S. Publi	shed Ap	plication	citation	n information p	olease click the Ad	d button	Add		
				FOREIG	SN PAT	ENT DOCUM	IENTS		Remove		
		Name of Patente Applicant of cited Document	or ,	vhere Rel	or Relevant	T5					
	1										С
If you wis	h to a	l dd additional Foreign P	atent Do	cument	citation	information pl	I lease click the Add	button	Add		_
			NON	1-PATE	NT LITE	RATURE DO	CUMENTS		Remove		
Examiner Initials*	Examiner Cite include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item nitials* No lobok, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), utilisher, city and/or country where publisher.										

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		11616659
iling Date		2003-07-09
rirst Named Inventor MARA		NNAS, Costas D.
Art Unit		1631
Examiner Name SKOV		VRONEK, Karlheinz R.
Attorney Docket Number		P06367US03

Supplementary European Search Report (co-pending EP 03 79 2962) dated April 11, 2007.							
	2 HATZIMANIKATIS, Vassily et al., "Analysis and design of metabolic reaction networks via mixed-integer linear optimization", A1ChE. Journal, 42(5):1277-1292 (1996).						
3 VARMA Amil et al., "Bochemical production capabilities of Escherichia coll", Biotechnology and Bioengineering, 42:59-73 (1993).							
	TORRES, Nestor V., et al., "An Indirect Optimization Method for Biochemical Systems: Description of Method and 4 Application to the Maximization of the Rate of Ehranol, Glycerol, and Carbolydrate Production in Saccharomyces cerevisiae", Biochemology and Bioengarenta, 56(5):756-72 (1997).						
	5 COVERT, M.W., et al., "Regulation of Gene Expression in Flux Balance Models of Metabolism", J. of Theoretical Biology, 213:73-88 (2001).						
If you wi	If you wish to add additional non-patent literature document citation information please click the Add button Add						
			EXAMINER SIGNATURE				
Examiner Signature				Date Considered			

18e Knr. Codes of USPTO Patent Documents at year (LSPTO_COL) or MPEP 90.04. 2 Enter office that issued the document, by the low-let for patent Sources (NIPO) Standard ST3.) 3 For Judianese patent focusinet, he endoud not on the year of the region or impresence the senti unique repeat document. 4 Knd of document by the appropriate symbols as indicated on the document under WIPO Standard ST1.6 if possole. 3 Applicant is to place a check mark here if English languages bersalted on a standard ST3.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		11616659	
	Filing Date		2003-07-09	
	First Named Inventor	MARANAS, Costas D.		
	Art Unit		1631	
	Examiner Name	SKOV	VRONEK, Karlheinz R.	
	Attorney Docket Number		P06367US03	

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

	That each item of information contained in the information disclosure statement was first cited in any communication
\times	from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
	information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(c).

٦	See	attached	certification	statement.

\neg	Fee set forth in 37	CFR 1 17 (n) ha	s been submitt	ed berewith

None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

oni or the agricule.							
Signature	/JOHN D. GOODHUE/	Date (YYYY-MM-DD)	2007-05-08				
Name/Print	JOHN D. GOODHUE	Registration Number	47603				

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenar's Office, U.S. operatment of Commence, P. 0. Box 1450, Alexandria, V.S. 2313-1450. D. ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.